CTP B级乙肝肝硬化失代偿期26例患者抗病毒治疗长期随访观察  

A long-term follow-up study of 26 patients with decompensated liver cirrhosis following hepatitis B of CTP B treated by antiviral treatment

作　　者：高勇[1] 罗秋红[1] 施光亚[1] 林燕玉[1] 

机构地区：[1]福建中医药大学附属人民医院消化内科,福州350004

出　　处：《福建医药杂志》2015年第6期4-6,共3页Fujian Medical Journal

摘　　要：目的探讨长期抗病毒治疗对乙肝肝硬化患者疾病转归的影响。方法对2008-2011年多次于我院住院治疗符合CTPB级诊断的26例乙肝后肝硬化长期随访并进行回顾性分析，随访时间30个月～7年，平均58个月，收集治疗前后右肝斜径、门静脉宽度、CTP评分、ALT、血清白蛋白、INR、住院次数及平均住院时间的数据，进行统计学分析。结果治疗后患者右肝斜径、门静脉宽度、CTP评分、ALT、血清白蛋白、INR、住院次数及平均住院时间均比治疗前有明显改善，且差异有统计学意义。结论长期的抗病毒治疗，对CTPB级的肝硬化患者，是一个安全有效的治疗手段。但用药期间仍需注意原发性肝癌的风险。Objective To investigate the effect of long-term antiviral treatment on the outcome and prognosis of patients with decompensated liver cirrhosis following hepatitis B. Methods Twenty-six inpatients in our hospital from 2008 to 2011 with decompensated liver cirrhosis following hepatitis B of CTP B were enrolled for a long-term follow-up and the retrospective analysis. Patients were followed up for 30 months to 7 years, averagely for 58 months. The oblique diameter of the right hepatic, the width of Portal vein, CTP score, the level of ALT, Serum albumin, INR, times of hospitalization and the average length of hospital stay before and after antiviral treatment were collected for statistical analysis. Results The oblique diameter of the right hepatic, the width of Portal vein, CTP score, the level of ALT, Serum albumin, INR, times of hospitalization and the average length of hospital stay after treatment were better than before, and there were statistically significant differences. Conclusion Long-term antiviral therapy is a safe and effective treatment for patients with decompensated liver cirrhosis following hepatitis B of CTP B, but we still need to pay attention to the risk of HCC during treatment.

关 键 词：乙型肝炎 乙肝后肝硬化 抗病毒治疗 随访 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]